Business · 03/06/2026Updated: 10/17/2026 · 1 min read
Vanda Pharmaceuticals to Face FDA Hearing on Proposed Refusal of HETLIOZ Supplemental Approval
Summary
The FDA is holding a public hearing on Vanda Pharmaceuticals' proposal to refuse approval of a supplemental new drug application for HETLIOZ (tasimelteon) to treat jet lag disorder, following a timely request from the company.